The method is available as a service from Single Cell Discoveries, and the researchers behind it are exploring several avenues of commercialization.

The Finnish firm will also use the money to build a quality control system so labs can validate their research pipelines.

The method, which incorporates a background reduction step into the existing approach, reported higher on-target sequencing depth and end-to-end read length. 

Researchers retraced historical migrations and relationships for Micronesian populations using genetic profiles for hundreds of ancient and modern individuals across the region.

With electronic health record and tumor panel sequence data from tens of thousands of cancer cases, researchers tallied relationships between gene alterations and patient outcomes.

The companies will build a diverse research cohort with multiomics data and apply AI as they seek to improve diagnostics and advance drug discovery.

The firm also plans to submit the assay to the US Food and Drug Administration for Emergency Use Authorization in the coming weeks.

The company has already launched a skin microbiome test for the consumer market and is now turning to diagnostics.

Analysis of 7,500 patients showed one-third had potentially actionable mutations and 10 percent were misdiagnosed, prompting calls for greater NGS use in this setting.

Scientists from the University of Florence in Italy applied nanopore sequencing to effectively detect known copy number variants in a small cohort of patients.

Based on dozens of ancient wolf genomes, researchers detected genetic connectedness during the Ice Age and proposed at least two wolf sources of dog domestication.

The acquisition will support continued product innovation in automated life science instruments and expansion into new geographies.

The PCR-based assay uses an extraction-free multiplex reagent to test orthopoxvirus and monkeypox gene targets in skin lesion samples. 

The San Jose, California-based infectious disease diagnostics company said it will use the funds to scale its production capacity and to add to its menu of tests.

ETH Zurich spinout Cytosurge develops single-cell research solutions and offers a CRISPR-based cell line engineering service.

The company plans to test and share genetic health risk data with 100,000 participants and their providers, aiming to improve patient care and outcomes.

The institute has awarded funding to a total of 12 sites to perform proteogenomic analyses on tumor samples and to study drug response and resistance.

The New York Times looks back at the 10 years since the University of California, Berkeley's Jennifer Doudna and her colleagues published their CRISPR paper.

Time Boost Capital has raised £30 million and will provide pound-for-pound matching funds to every Illumina Accelerator Cambridge graduate that meets certain conditions.

The kit is provided in a 48-well microplate format and is compatible with automated reaction protocols.

BioGX previously helped develop a monkeypox and orthopoxvirus assay on the GeneXpert that was validated on clinical samples in 2017.

Started by three UC Berkeley dropouts and fresh off a $28 million Series A, LatchBio seeks to bridge the gap between biologists and bioinformaticians with its software ecosystem.

The firm is commercializing technology to analyze degraded DNA developed by the paleogenomics lab at the University of California, Santa Cruz.

The firms have had an alliance for the past two years and market a respiratory pathogen panel.

A prospective, multicenter study involving 345 children or young adults with cancer suggested tumor panel sequencing can help guide treatment, improve diagnoses, or inform prognoses.